Stromal factors involved in prostate carcinoma metastasis to bone

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 739-747

  Cooper, Carlton R ^a   Chay, Christopher H ^a   Gendernalik, James D ^a   Lee, Hyung Lae ^a   Bhatia, Jasmine ^a   Taichman, Russell S ^b   McCauley, Laurie K ^b,c   Keller, Evan T ^c   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b School of Dentistry   (United States)

^c Temple University School of Medicine   (United States)

Author keywords

Bone metastasis; Cell adhesion; Chemotactic factors; Cytokines; Prostate carcinoma; Thrombin

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CHEMOTACTIC FACTOR; COLLAGEN TYPE 1; STROMAL CELL DERIVED FACTOR 1; THROMBIN; TRANSFORMING GROWTH FACTOR BETA;

BONE METASTASIS; CANCER GROWTH; CELL ADHESION; CELL INTERACTION; CELL SURVIVAL; CONFERENCE PAPER; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; METASTASIS POTENTIAL; MICROENVIRONMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0037304044     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11181     Document Type: Conference Paper

References (58)

1. Rubin MA, Putzi M, Mucci N, et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000;6:1038-1045.
2. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol. 2000;31:578-583.
3. Rubens RD. Bone metastases - the clinical problem. Eur J Cancer. 1998;34:210-213.
4. 4. Orr FW, Lee J, Duivenvoorden WCM, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer. 2000;88: 2912-2918.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
6. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 1989; 49:2525-2535.
7. Liotta LA, Kohn EC. The microenvironment of the tumourhost interface. Nature. 2001;411:375-379.
8. Rigg AS, Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther. 2001;2001:869-878.
9. Chay CH, Cooper CR, Gendernalik JD, et al. The expression of a functional thrombin receptor (PAR1) is associated with bone-derived prostate cancer cell lines [abstract 1564]. Proc Am Assoc Cancer Res. 2002;43:315.
10. Liu Y, Gilcrease MZ, Henderson Y, Yuan XH, Clayman GL, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Lett. 2001;169:173-180.
11. Henrikron KP, Salazar SL, Fenton JW, Pentecost BT. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer. 1999;79:401-406.
12. Monsky WL, Carreira CM, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumor. Clin Cancer Res. 2002;4:1008-1013.
13. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metast. 1994;14:303-308.
14. Ruf W, Fischer EG, Huang HY, et al. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol Res. 2000;21:289-292.
15. Carmeliet P. Clotting factors build blood vessels. Science. 2001;293:1602-1604.
16. Lafleur MA, Hollenberg MD, Atkinson SJ, Uper VK, Murphy G, Edwards DR. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMPdependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. J Biochem. 2001; 357:107-115.
17. Korenchuk S, Lehr JE, McLean L, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001;15: 163-168.
18. Lee Y-G, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo. 2001;15:157-162.
19. Gopalkrishnan RV, Kang D-C, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol. 2001;189:245-256.
20. Biggerstaff JP, Seth N, Amirkhasravi A, et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metast. 1999;17:723-730.
21. Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived chemoattractants. Cancer Res. 1985;45:3517-3521.
22. Yoneda T. Mechanisms of preferential metastasis of breast cancer to bone [review]. Int J Oncol. 1996;9:103-109.
23. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis. 2000;3:6-12.
24. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000;269:652-659.
25. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-1837.
26. Pauli BU, Lee C-L. Organ preference of metastasis: the role of organ-specifically modulated endothelial cells. Lab Invest. 1988;58:379-387.
27. Voura EB, Sandig M, Siu C-H. Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech. 1998;43:265-275.
28. Jahroudi N, Greenberger JS. The role of endothelial cells in tumor invasion and metastasis. J Neurooncology. 1995;23: 99-108.
29. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Mushel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model of metastasis. Nat Med. 2000;6:100-102.
30. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998;90:118-123.
31. Cooper CR, Mclean L, Walsh M, et al. Preferential adhesion to prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res. 2000;6:4839-4847.
32. Scott L, Clarke N, George N, Shanks J, Testa N, Lang S. Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer. 2001;84:1417-1423.
33. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metast Rev. 1992; 11:353-375.
34. Simpson MA, Reiland J, Burger SR, et al. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem. 2001;276:17949-17957.
35. Kierszenbaum AL, Rivkin E, Chang PL, Tres LL, Olsson CA. Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells. Prostate. 2000;43:175-183.
36. Cooper CR, McLean L, Mucci NR, Poncza P, Pienta KJ. Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. Anticancer Res. 2000;20:4159-4162.
37. Romanov VI, Goligorsky MS. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate. 1999;39:108-118.
38. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997;3:2493-2500.
39. Nakhla AM, Rosner W. Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Steriods. 1994;59:586-589.
40. Augustin-Voss HG, Johnson RC, Pauli BU. Modulation of endothelial cell surface glycoconjugate expression by organderived biomatrices. Exp Cell Res. 1991;192:346-351.
41. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and Eselectin expression in the liver in response to metastatic tumor cells. Cancer Res. 1999;59:1356-1361.
42. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol. 1996;156:2558-2565.
43. Kostenuik PJ, Singh G, Orr FW. Transforming growth factorbeta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to Type I collagen. Clin Exp Metast. 1997;15:41-52.
44. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop. 1991;263:30-48.
45. Cooper CR, Bhatia JK, Muenchen HJ, et al. The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin Exp Metast. 2002;19:25-33.
46. Cohen MC, Bereta M, Bereta J. Effect of cytokines on tumour cell-endothelial interactions. Indian J Biochem Biophys. 1997;1-2:199-204.
47. Festuccia C, Bologna M, Gravina GL, et al. Osteoblast conditioned media contained TGF-betal and modulated the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer. 1999;81:395-403.
48. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 1999;99:2317-2322.
49. Nissinen L, Pirila L, Heino J. Bone morphogenetic protein-2 is a regulator of cell adhesion. Exp Cell Res. 1997;230:377-385.
50. Koeneman KS, Yeung F, Chung LWK. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246-261.
51. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate. 1994;24:204-211.
52. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P, Maragoudakis M-EM. Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol. 2000;19:345-351.
53. Amerongen GPVN, Delft SV, Vermeer MA, Collard JG, Hinsbergh VWMV. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res. 2000;87:335-340.
54. Maragoudakis ME, Tsopanoglou NE. On the mechanism(s) of thrombin induced angiogenesis. Adv Exp Med Biol. 2000; 476:47-55.
55. Dittmar T, Gloria-Maercker E, Thomas-Ecker S, Zanker KS, Heyder C. A novel in vitro model for realtime visualization of tumor cells invading an endothelial barrier during blood-borne metastasis [abstract 2687]. Proc Am Assoc Cancer Res. 2002;43:541.
56. Lee H-L, Cooper CR, Pienta KJ. The effect of growth factors and cytokines on the growth of androgen sensitive and insensitive human prostate cancer cells in vitro [abstract 941]. Proc Am Assoc Cancer Res. 2002;43:187.
57. Lamm ML, Podlasek CA, Barnett DH, et al. Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol. 2001;232:301-314.
58. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in nonmetastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate. 2002; 51:10-20.